Objective: This article adopts the perspective of psychosomatic medicine to present and test a theoretical model of the classification of clinical somatic symptoms. The theoretical model consists of four dimensions: emotional somatic symptoms, biological somatic symptoms, imaginative somatic symptoms, and cognitive somatic symptoms.
Method: A clinical somatic symptom classification scale was developed according to the theoretical model. A total of 542 participants completed the clinical somatic symptoms classification scale. The data were analyzed using exploratory and confirmatory factor analyses.
Results: The results confirmed the theoretical model. The analyses found that the proposed theoretical structure of the scale was good, as indicated by factor loadings and fit indices, and that the scale had good reliability and construct validity.
Conclusions: Based on the interpretation of the clinical symptoms of psychosomatic medicine, the treatment of chronic non-infectious diseases includes at least three dimensions: the first is the etiological treatment, the second is the pathophysiological and pathopsychological dimension, and the third is symptomatic treatment. The unified psychosomatic point of view and diverse clinical thinking modes are aimed at identifying different classes of somatic symptoms and important prerequisites for the treatment of these symptoms. We registered the study with the Chinese Clinical Trial Registry and it was approved by the West China Hospital, Sichuan University ethics committee.
Trial Registration: The registration number is ChiCTR-OCS-14004632 (time: 2014-05-12).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985123 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161222 | PLOS |
Int J Mol Sci
January 2025
Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 13353 Berlin, Germany.
Epilepsy affects 50 million people worldwide and is drug-resistant in approximately one-third of cases. Even when a structural lesion is identified as the epileptogenic focus, understanding the underlying genetic causes is crucial to guide both counseling and treatment decisions. Both somatic and germline DNA variants may contribute to the lesion itself and/or influence the severity of symptoms.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Clinical Psychology, University of Dhaka, Bangladesh.
Background: The absence of a reliable and valid Bangla instrument for measuring somatic symptom disorder hinders research and clinical activities in Bangladesh. The present study aimed at translating and validating the Somatic Symptom Disorder-B criteria (SSD-12).
Method: A cross-sectional design was used with purposively selected clinical (n = 100) and non-clinical (n = 100) samples.
J Pers Med
December 2024
Divisione di Cardiologia, Policlinico Casilino, Via Casilina, 00169 Roma, Italy.
: Takotsubo syndrome (TTS) shares many clinical features with acute myocardial infarction (AMI); however, its underlying pathophysiology remains elusive due to specific characteristics (i.e., reversibility, presence of stressors, and low mortality rate).
View Article and Find Full Text PDFBehav Sci (Basel)
January 2025
The Global Village NGO, Bagni di Lucca, 55022 Lucca, Italy.
Mind-body practices have shown to be effective in reducing psychological distress and improving well-being and quality of life in clinical samples and healthy populations. We tested the effects of a body-based mindfulness intervention based on alexithymia, distress symptoms, and dispositional mindfulness among healthy adults. A total of seventy-three participants (mean age 40.
View Article and Find Full Text PDFCells
January 2025
Department of Histology and Embryology and Vascular Biology Student Research Club, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-092 Bydgoszcz, Poland.
Cardiovascular diseases (CVDs) remain a significant global health challenge, with many current treatments addressing symptoms rather than the genetic roots of these conditions. The advent of CRISPR-Cas9 technology has revolutionized genome editing, offering a transformative approach to targeting disease-causing mutations directly. This article examines the potential of CRISPR-Cas9 in the treatment of various CVDs, including atherosclerosis, arrhythmias, cardiomyopathies, hypertension, and Duchenne muscular dystrophy (DMD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!